A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Trial Profile

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Carboplatin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Rituximab; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 Aug 2017 Planned number of patients changed from 84 to 96.
    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 Planned End Date changed from 31 Mar 2024 to 21 Mar 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top